FULGENT GENETICS, INC. Equity Method Investment, Other than Temporary Impairment
FULGENT GENETICS, INC. (FLGT) reported Equity Method Investment, Other than Temporary Impairment of $1.76 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment · last filed 2021-03-08
- FULGENT GENETICS, INC. equity method investment, other than temporary impairment for the quarter ending 2020-12-31 was $1.76M.
- FULGENT GENETICS, INC. equity method investment, other than temporary impairment for the quarter ending 2020-09-30 was $2.59M.
- FULGENT GENETICS, INC. equity method investment, other than temporary impairment for fiscal 2020 was $4.35M.
| Period end | Equity Method Investment, Other than Temporary Impairment 3 month | Equity Method Investment, Other than Temporary Impairment 6 month | Equity Method Investment, Other than Temporary Impairment 9 month | Equity Method Investment, Other than Temporary Impairment 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.76M 10-K · filed 2021-03-08 | $4.35M derived: sum of 2 quarters · filed 2021-03-08 | $4.35M 10-K · filed 2021-03-08 | |
| 2020-09-30 | $2.59M 10-K · filed 2021-03-08 | $2.59M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |